Noxopharm Limited (ASX:NOX) is trading ~5 per cent higher (as at 12:01 PM AEST) following the release of its Corporate Presentation for the Reach Markets Virtual Event.
Noxopharm is focused on arguably the biggest prize in the pharma industry by developing a drug that is anticipated to make the current generation of immuno-oncology (I-O) anti-cancer drugs work much better.
Noxopharm believes Veyonda® can be a solution to increase the response to I-O drugs. While converting cold tumours to hot tumours is a multi-billion-dollar challenge, Noxopharm’s Veyonda® has confirmed this in the laboratory.
Veyonda®, together with radiation therapy, appeared to be well-tolerated and safe in DARRT-1 Phase 1 study while providing proof-of-concept efficacy signals in cancer type with current poor I-O drug outcomes. Noxpharm is now targeting commencement of DARRT-2 Phase 2 study in early 2021.